Key points are not available for this paper at this time.
Type 2 diabetes is a chronic and multifactorial disease associated with a twofold increase in the incidence of numerous cardiovascular and renal diseases, which are a significant health limitation for patients with diabetes. Throughout the years, cardiovascular diseases have marked a significant health burden in these patients. Many studies have shown that Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce cardiovascular mortality in patients with diabetes mellitus, by inhibiting cardiomyocyte apoptosis. Patients with diabetes are at a higher mortality risk after their first event of myocardial infarction than those without diabetes. The keystone in the therapy of diabetic patients is significantly linked to the prevention of cardiovascular events. The high prevalence of cardiovascular and renal disease in patients with diabetes, as well as suboptimal glycemic controls and the significance of cardiovascular and renal risk reduction in type 2 diabetes, suggest that SGLT2 inhibitors have a significant clinical advantage, enhancing not just a better glycemic control, but improving cardiovascular and renal outcomes.
Rico et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: